There were 337 press releases posted in the last 24 hours and 437,686 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image